Synthesis and Study of Antimicrobial Activity of 2-Dithiocarbamate-N-(9,10-Dioxo-9,10-Dihydroanthracenyl)Acetamides

Viktor Zvarych 1, Maryna Stasevych 1,*, Volodymyr Novikov 1, Mykhailo Vovk 2

1 Department of Technology of Biologically Active Substances, Pharmacy, and Biotechnology, Lviv Polytechnic National University, 13, 79013 Lviv, Ukraine
2 Department of Mechanism of Organic Reactions, Institute of Organic Chemistry of National Academy of Sciences of Ukraine, 02660 Kyiv, Ukraine
* Correspondence: maryna.v.stasevych@lpnu.ua; Scopus Author ID 8636372500

Abstract: The global emergence and dissemination of multidrug-resistant fungal and bacterial pathogens is a serious public health threat. The development of novel highly active antimicrobial compounds simultaneously targeting several targets in bacterial or fungal pathogens could help to fight antimicrobial resistance. The four-component one-pot two-step facile synthesis of a new 2-dithiocarbamate-N-(9,10-dioxo-9,10-dihydroanthracenyl)acetamides 3a-n by the interaction of 2-chloro-N-(9,10-dioxo-9,10-dihydroanthracenyl)acetamide 1 or 2 with a series of in situ generated potassium salt of dithiocarbamic acids in DMF-H2O is presented. Evaluation of the antimicrobial activity of the synthesized compounds against bacteria strains Escherichia coli В-906, Staphylococcus aureus 209-Р, Mycobacterium luteum В-917, and fungi Candida tenuis VKM Y-70, Aspergillus niger VKM F-1119 has been carried out by the diffusion in agar method and by the serial dilution technique. It has been established that synthesized compounds 3a, 3i, 3j have the good antibacterial activity against strain M. luteum at a concentration of 0.5% and the dithiocarbamates 3b, 3i, 3j, 3n demonstrate antifungal effect against C. tenuis at the same concentration. The results of the serial dilution technique showed that compound 3j has high antibacterial action at MIC 3.9 μg/ml.

Keywords: 2-chloro-N-(9,10-dioxo-9,10-dihydroanthracenyl)acetamide; dithiocarbamates; in vitro study; antibacterial activity; antifungal activity.

© 2020 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

1. Introduction

The global emergence and dissemination of multidrug-resistant (MDR) Mycobacterium tuberculosis, Staphylococcus aureus, and non-fermentative Gram-negative bacilli such as Pseudomonas aeruginosa is an increasingly important global public health concern [1-2]. Moreover, lack of active antifungal agents, rising antifungal resistance, and emergence of MDR fungal pathogens is a serious public health threat [3-9]. MDR organisms generated in clinical or veterinarian sectors can persist in the environment, are capable of colonizing hosts, and then spread outside primary sites (farms, hospitals). Once the colonized host immune system is impaired, MDR fungal and bacterial pathogens can cause devastating infections that are often non-responsive to standard and even last-line treatment options. Therefore, the development of novel highly active antimicrobial compounds simultaneously targeting several targets in bacterial or fungal pathogens could help to fight antimicrobial resistance.
Dithiocarbamates are valuable synthetic products [10] and are a class of perspective compounds with different types of biological activities. In particular, antibacterial and antifungal agents [11-18] were found among them. The functionalization of dithiocarbamates with biophore fragments has proven to be especially useful in creating combinatorial libraries for rapid screening [19] and drug design [20-22].

From the other side, the anthraquinone core is one of the key quinone molecular platforms, which has a strong synthetic, applied, and pharmacological potential [23-24]. The substances with a high antimicrobial effect were revealed among anthraquinone derivatives of both natural and synthetic origin [25-30].

In the context of the above, the aim of our work was the synthesis of a new hybrid anthraquinone-dithiocarbamate derivatives and the investigation of their antibacterial and antifungal properties for identifying potential antimicrobial agents among them.

2. Materials and Methods

2.1. Materials.

All chemicals were of reagent grade and used without further purification. The solvents were purified according to the standard procedures [31]. The initial 2-chloroacetamides 1,2 were prepared from 1-amino-9,10-dioxo-9,10-dihydroanthracene (Sigma-Aldrich) and 2-amino-9,10-dioxo-9,10-dihydroanthracene (Sigma-Aldrich) according to the method described in [26].

2.2. Chemistry.

Melting points were measured on a Boetius melting point-device and are uncorrected. 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra were recorded in DMSO-d6 solutions on a Varian Mercury-400 spectrometer with TMS as an internal standard. Mass spectra were recorded on an Agilent 1100 Series G1956BLC/MSD SL LCMS system using electrospray ionization at atmospheric pressure (70 eV). Elemental analysis was performed on a PerkinElmer CHN-analyzer Series 2400. The individuality of the obtained compounds was monitored by TLC on Silufol UV-254 plates.

General procedure for the synthesis of 2-dithiocarbamate-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamides 3a-n. To 1 ml of water, 0.103 g (1.87 mmol) of KOH, 10 ml of dimethylformamide, 1.87 mmol of the corresponding secondary amine, and 0.12 ml (1.87 mmol) of carbon disulfide were successively added and stirred at room temperature for 1 h (with dicyclohexylamine 12 h). Then 0.5 g (1.70 mmol) of 2-chloro-N-acetamide 1 or 2 in 40 ml of dimethylformamide was added to the mixture, and stirred for 1 h. Then it was heated at 70 °C for 5 hours. The reaction mixture was cooled, and 150 ml of water was added. The precipitate formed was filtered off, washed with water and dried.

2-((9,10-Dioxo-9,10-dihydroanthracen-1-yl)amino)-2-oxoethyl azepane-1-carbodithioate 3a. Yield 74%; m.p.: 184 °C (decomposition). 1H NMR: δ = 12.48 (br. s, 1H, NH), 8.95 (dd, 1H, J = 17.1, 8.0 Hz, CHar), 8.19-8.07 (m, 2H, CHar), 7.94-7.81 (m, 4H, CHar), 4.34 (s, 2H, CH2), 4.16-4.06 (m, 4H, CH2), 2.04-1.88 (m, 2H, CH2), 1.64-1.44 (m, 4H, CH2). 13C NMR: δ = 193.51 (C=S), 186.64, 182.45, 167.82 (C=O), 141.43, 136.16, 135.10, 134.31, 134.02, 132.76, 127.25, 126.92, 125.66, 122.49, 118.31 (C=ar), 55.96, 53.38, 41.42, 27.95, 27.29, 26.47, 25.91 (CH2). LC-MS: m/z = 439 [M+1] (100%). Anal. Calcd.
2-((9,10-Dioxo-9,10-dihydroanthracen-1-yl)amino)-2-oxoethyl dibenzylcarbamodithioate 3b. Yield 75%; m.p.: 195 °C (decomposition). \(^1\)H NMR: \(\delta = 12.64\) (br. s, 1H, NH), 9.01 (dd, 1H, \(J = 8.3\) Hz, \(CH_2\)), 8.12 (m, 2H, \(CH_2\)), 7.96-7.85 (m, 4H, \(CH_2\)), 7.41-7.07 (m, 10H, \(CH_2\)), 5.32-5.23 (m, 4H, \(CH_2\)). 13C NMR: \(\delta = 197.03\) (C=S), 186.77, 182.48, 167.57 (C=O), 141.45, 136.38, 135.70, 135.30, 135.22, 135.10, 134.26, 133.83, 132.65, 129.38, 128.82, 128.27, 127.76, 127.55, 126.92, 125.46, 122.57, 118.05 (C=ar), 57.72, 55.46, 42.09 (CH2). LC-MS: \(m/z = 537\) [M+1] (100%). Anal. Calcd. for C\(_{31}\)H\(_{24}\)N\(_2\)O\(_5\)S\(_2\), %: C 69.38; H 4.51; N 5.22; S 11.95. Found, %: C 69.43; H 4.46; N 5.27; S 11.91.

2-((9,10-Dioxo-9,10-dihydroanthracen-1-yl)amino)-2-oxoethyl dibutylcarbamodithioate 3c. Yield 92%; m.p.: 197 °C (decomposition). \(^1\)H NMR: \(\delta = 12.49\) (br. s, 1H, NH), 8.95 (dd, 1H, \(J = 15.0\), 8.2 Hz, \(CH_2\)), 8.18-8.07 (m, 3H, \(CH_2\)), 7.97-7.81 (m, 3H, \(CH_2\)), 4.34 (d, 2H, \(J = 9.2\) Hz, \(CH_2\)), 3.90 (s, 4H, \(CH_2\)), 1.91-1.78 (m, 2H, \(CH_2\)). 13C NMR: \(\delta = 134.23, 133.83, 132.65, 129.38, 128.82, 128.27, 127.76, 127.55, 126.92, 125.46, 122.57, 118.05\) (C=ar), 57.72, 55.46, 42.09 (CH2). LC-MS: \(m/z = 537\) [M+1] (100%). Anal. Calcd. for C\(_{31}\)H\(_{24}\)N\(_2\)O\(_5\)S\(_2\), %: C 69.38; H 4.51; N 5.22; S 11.95. Found, %: C 69.43; H 4.46; N 5.27; S 11.91.

2-((9,10-Dioxo-9,10-dihydroanthracen-1-yl)amino)-2-oxoethyl dipropylcarbamodithioate 3d. Yield 69%; m.p.: 199 °C (decomposition). \(^1\)H NMR: \(\delta = 12.49\) (br. s, 1H, NH), 8.95 (dd, 1H, \(J = 8.0\) Hz, \(CH_2\)), 8.09 (d, 2H, \(J = 6.7\) Hz, \(CH_2\)), 7.90-7.86 (m, 4H, \(CH_2\)), 4.33 (d, 2H, \(J = 6.7\) Hz, \(CH_2\)), 3.90-3.85 (m, 4H, \(CH_2\)), 1.92-1.85 (m, 2H, \(CH_2\)), 1.69-1.62 (m, 2H, \(CH_2\)), 1.02 (t, 3H, \(J = 6.9\) Hz, \(CH_3\)), 0.80 (t, 3H, \(J = 7.1\) Hz, \(CH_3\)). 13C NMR: \(\delta = 139.35\) (C=S), 186.66, 182.52, 167.71 (C=O), 141.37, 136.20, 135.16, 134.29, 134.01, 132.71, 127.39, 127.22, 126.92, 125.58, 125.49, 118.36 (C=ar), 57.09, 54.68, 41.79, 20.88, 19.47 (CH2), 11.57, 11.37 (CH3). LC-MS: \(m/z = 442\) [M+1] (100%). Anal. Calcd. for C\(_{31}\)H\(_{24}\)N\(_2\)O\(_5\)S\(_2\), %: C 69.38; H 4.51; N 5.22; S 11.95. Found, %: C 69.43; H 4.46; N 5.27; S 11.91.

2-((9,10-Dioxo-9,10-dihydroanthracen-1-yl)amino)-2-oxoethyl dicyclohexylcarbamodithioate 3e. Yield 71%; m.p.: 243 °C (decomposition). \(^1\)H NMR: \(\delta = 12.45\) (br. s, 1H, NH), 8.94 (dd, 1H, \(J = 24.2\), 7.3 Hz, \(CH_2\)), 8.16-8.05 (m, 2H, \(CH_2\)), 7.89-7.81 (m, 3H, \(CH_2\)), 4.33 (s, 2H, \(CH_2\)), 4.29-4.22 (m, 4H, \(CH_2\)), 2.05-1.15 (m, 20H, \(CH_2\)). 13C NMR: \(\delta = 139.35\) (C=S), 186.74, 182.46, 167.69 (C=O), 141.28, 136.20, 135.18, 135.13, 134.23, 133.96, 132.70, 132.65, 127.37, 126.90, 125.56, 125.49, 118.26 (C=ar), 56.46 (CH), 41.80, 35.10, 26.01, 24.73 (CH2). LC-MS: \(m/z = 522\) [M+1] (100%). Anal. Calcd. for C\(_{31}\)H\(_{24}\)N\(_2\)O\(_5\)S\(_2\), %: C 66.89; H 6.19; N 5.38; S 12.31. Found, %: C 66.94; H 6.15; N 5.43; S 12.39.

2-((9,10-Dioxo-9,10-dihydroanthracen-1-yl)amino)-2-oxoethyl diethylcarbamodithioate 3f. Yield 78%; m.p.: 201 °C (decomposition). \(^1\)H NMR: \(\delta = 12.57\) (br. s, 1H, NH), 9.00 (m, 1H, \(CH_2\)), 8.16 (m, 2H, \(CH_2\)), 7.93 (m, 4H, \(CH_2\)), 4.33 (d, 2H, \(J = 6.7\) Hz, \(CH_2\)), 3.97 (m, 4H, \(CH_2\)), 1.42 (t, 3H, \(J = 7.0\) Hz, \(CH_3\)), 1.14 (t, 3H, \(J = 7.1\) Hz, \(CH_3\)). 13C NMR: \(\delta = 192.72\) (C=S), 186.62, 182.45, 167.78 (C=O), 141.40, 136.15, 135.13, 134.30, 134.00, 132.75, 127.27, 126.92, 125.66, 122.49, 118.32 (C=ar), 50.13, 47.50, 41.40 (CH2), 12.92, 11.68 (CH3). LC-MS: \(m/z = 414\) [M+1] (100%). Anal. Calcd. for C\(_{32}\)H\(_{20}\)N\(_2\)O\(_3\)S\(_2\), %: C 61.14; H 4.89; N 6.79; S 15.54. Found, %: C 61.20; H 4.81; N 6.83; S 15.61.
2-((9,10-Dioxo-9,10-dihydroanthracen-1-yl)amino)-2-oxoethyl 1H-imidazole-1-carbodithioate 3g. Yield 75%; m.p.: 187 °C (decomposition).<ref>
H NMR: δ = 12.32 (br. s, 1H, NH), 8.90-8.80 (m, 1H, CH₉), 8.08-7.95 (m, 3H, CH₉+imidazole), 7.88-7.62 (m, 6H, CH₉+imidazole), 4.39 (d, 2H, J = 7.3 Hz, CH₂).<ref>
13C NMR: δ = 194.17 (C=S), 186.70, 182.30, 167.55 (C=O), 141.29, 140.74, 136.07, 135.09, 134.27, 133.93, 132.69, 127.49, 127.35, 126.87, 125.81, 125.72, 122.95, 122.46, 118.36 (C₉), 44.06 (CH₂).<ref>
LC-MS: m/z = 408 [M+1] (100%).<ref>
Anal. Calcd. for C₂₀H₁₃N₃O₃S₂, %: C 58.96; H 3.22; N 10.31; S 15.74. Found, %: C 58.91; H 3.25; N 10.35; S 15.69.<ref>

2-((9,10-Dioxo-9,10-dihydroanthracen-1-yl)amino)-2-oxoethyl morpholine-4-carbodithioate 3h. Yield 89%; m.p.: 226 °C (decomposition).<ref>
H NMR: δ = 12.50 (br. s, 1H, NH), 8.99-8.94 (m, 1H, CH₉), 8.18-8.10 (m, 2H, CH₉), 7.89 (m, 4H, CH₉), 4.37 (d, 2H, J = 17.2 Hz, CH₂), 4.21-4.16 (m, 4H, CH₂), 3.81-3.70 (m, 4H, CH₂).<ref>
13C NMR: δ = 194.15 (C=S), 186.89, 182.64, 162.77 (C=O), 136.24, 135.21, 132.81, 127.32, 126.98, 125.59, 125.51, 122.57 (C₉), 66.10, 66.02, 52.21, 51.27, 42.07 (CH₂).<ref>
LC-MS: m/z = 428 [M+1] (100%).<ref>
Anal. Calcd. for C₂₁H₁₈N₃O₃S₂, %: C 59.14; H 4.25; N 6.57; S 15.03. Found, %: C 59.18; H 4.21; N 6.62; S 15.09.<ref>

2-((9,10-Dioxo-9,10-dihydroanthracen-1-yl)amino)-2-oxoethyl pyrrolidine-1-carbodithioate 3i. Yield 80%; m.p.: 210 °C (decomposition).<ref>
H NMR: δ = 12.40 (br. s, 1H, NH), 8.98-8.88 (m, 1H, CH₉), 8.24-8.08 (m, 2H, CH₉), 8.00-7.80 (m, 4H, CH₉), 4.34 (s, 2H, CH₂), 3.94-3.76 (m, 4H, CH₂), 2.19-2.09 (m, 2H, CH₂), 2.04-1.92 (m, 2H, CH₂).<ref>
13C NMR: δ = 189.81 (C=S), 186.70, 182.45, 167.68 (C=O), 141.38, 136.06, 135.09, 134.39, 134.13, 132.83, 127.27, 126.92, 125.81, 122.53, 118.56 (C₉), 55.90, 51.35, 39.75, 26.21, 24.32 (CH₂).<ref>
LC-MS: m/z = 412 [M+1] (100%).<ref>
Anal. Calcd. for C₂₁H₁₈N₃O₃S₂, %: C 61.44; H 4.42; N 6.82; S 15.62. Found, %: C 61.49; H 4.37; N 6.76; S 15.69.<ref>

2-((9,10-Dioxo-9,10-dihydroanthracen-2-yl)amino)-2-oxoethyl azepane-1-carbodithioate 3j. Yield 90%; m.p.: 175 °C (decomposition).<ref>
H NMR: δ = 10.82 (br. s, 1H, NH), 8.41-8.39 (m, 1H, CH₉), 8.14-8.10 (m, 3H, CH₉), 8.01 (d, 1H, J = 8.4 Hz, CH₉), 7.88-7.85 (m, 2H, CH₉), 4.31 (s, 2H, CH₂), 4.13-4.09 (m, 2H, CH₂), 3.97-3.92 (m, 2H, CH₂), 1.84-1.74 (m, 4H, CH₂), 1.53-1.49 (m, 4H, CH₂).<ref>
13C NMR: δ = 194.39 (C=S), 182.79, 181.70, 166.93 (C=O), 144.88, 134.96, 134.62, 134.56, 133.54, 133.50, 128.93, 128.41, 127.15, 127.07, 124.14, 116.25 (C₉), 55.69, 53.12, 41.80, 27.25, 26.57, 26.39, 25.99 (CH₂).<ref>
LC-MS: m/z = 440 [M+1] (100%).<ref>
Anal. Calcd. for C₂₃H₂₂N₂O₃S₂, %: C 62.99; H 5.06; N 6.39; S 14.62. Found, %: C 62.92; H 5.11; N 6.31; S 14.54.<ref>

2-((9,10-Dioxo-9,10-dihydroanthracen-2-yl)amino)-2-oxoethyl diethylcarbamodithioate 3k. Yield 79%; m.p.: 210 °C (decomposition).<ref>
H NMR: δ = 10.76 (br. s, 1H, NH), 8.43-8.41 (m, 1H, CH₉), 8.17-8.15 (m, 2H, CH₉), 8.14-8.13 (m, 1H, CH₉), 8.04 (d, 1H, J = 8.5 Hz, CH₉), 7.89-7.86 (m, 2H, CH₉), 4.32 (s, 2H, CH₂), 3.98-3.83 (m, 4H, CH₂), 1.24 (s, 6H, CH₃).<ref>
13C NMR: δ = 193.62 (C=S), 182.81, 181.72, 166.95 (C=O), 144.89, 134.98, 134.64, 134.59, 133.55, 133.52, 128.96, 128.42, 127.16, 127.08, 124.14, 116.24 (C₉), 49.84, 47.28, 41.80 (CH₂), 12.91, 11.82 (CH₃).<ref>
LC-MS: m/z = 414 [M+1] (100%).<ref>
Anal. Calcd. for C₂₁H₁₂₀₂N₂O₂S₂, %: C 61.14; H 4.89; N 6.79; S 15.54. Found, %: C 61.19; H 4.95; N 6.83; S 15.48.<ref>

2-((9,10-Dioxo-9,10-dihydroanthracen-2-yl)amino)-2-oxoethyl 4-methylpiperazine-1-carbodithioate 3l. Yield 80%; m.p.: 147 °C (decomposition).<ref>
H NMR: δ = 10.91 (br. s, 1H, NH), 8.37-8.35 (m, 1H, CH₉), 8.09-8.04 (m, 3H, CH₉), 7.99 (d, 1H, J = 7.9 Hz, CH₉), 7.83-7.81 (m, 2H, CH₉), 4.32 (d, 2H, J = 11.9 Hz, CH₂), 4.17-3.93 (m, 4H, CH₂), 2.41-2.39 (m, 4H,
CH₂), 2.20 (s, 3H, CH₃). ¹³C NMR: δ = 194.93 (C=S), 182.72, 181.62, 166.86 (C=O), 144.87, 134.89, 134.55, 134.49, 133.48, 128.85, 128.35, 127.10, 127.02, 124.10, 116.23 (C₆H₅), 54.45, 54.43, 50.21 (CH₂), 45.55 (CH₃), 41.91 (CH₂). LC-MS: m/z = 441 [M+1] (100%). Anal. Calcd. for C₃₂H₂₁N₃O₃S₂, %: C 60.12; H 4.82; N 9.56; S 14.59. Found, %: C 60.18; H 4.76; N 9.59; S 14.62.

2-((9,10-Dioxo-9,10-dihydroanthracen-2-yl)amino)-2-oxyethyl morpholine-4-carbodithioate 3m. Yield 78%; m.p.: 232 °C (decomposition). ¹H NMR: δ = 10.88 (br. s, 1H, NH), 8.42-8.38 (m, 1H, CH₆H₅), 8.16-8.09 (m, 3H, CH₆H₅), 8.02 (d, J = 8.4 Hz, CH₆H₅), 7.90-7.84 (m, 2H, CH₆H₅), 4.35 (s, 2H, CH₂), 4.20-4.01 (m, 4H, CH₂), 3.71-3.68 (m, 4H, CH₂).

13C NMR: δ = 195.36 (C=S), 182.81, 181.73, 166.80 (C=O), 144.86, 134.98, 134.63, 134.56, 128.96, 128.46, 127.16, 127.09, 124.16, 116.27 (C₆H₅), 66.06, 51.91, 51.03, 41.60 (CH₂).

LC-MS: m/z = 428 [M+1] (100%). Anal. Calcd. for C₂₁H₁₈N₂O₄S₂, %: C 59.14; H 4.25; N 6.57; S 15.03. Found, %: C 59.19; H 4.19; N 6.59; S 15.00.

2-((9,10-Dioxo-9,10-dihydroanthracen-2-yl)amino)-2-oxyethyl pyrrolidine-1-carbodithioate 3n. Yield 95%; m.p.: 206 °C (decomposition). ¹H NMR: δ = 10.84 (br. s, 1H, NH), 8.40 (s, 1H, CH₆H₅), 8.16-8.11 (m, 3H, CH₆H₅), 8.04-8.01 (m, 1H, CH₆H₅), 7.89-7.86 (m, 2H, CH₆H₅), 4.32 (s, 2H, CH₂), 3.77 (t, J = 6.7 Hz, CH₂), 3.69 (t, J = 6.7 Hz, CH₂), 2.08-2.03 (m, 2H, CH₂), 1.95-1.91 (m, 2H, CH₂). ¹³C NMR: δ = 193.49 (C=S), 182.19, 181.69, 166.87 (C=O), 138.59, 135.11, 133.69, 133.42, 133.34, 132.12, 130.42, 128.11, 127.42 (C₆H₅), 57.39, 51.48, 41.81, 26.55, 24.12 (CH₂). LC-MS: m/z = 412 [M+1] (100%). Anal. Calcd. for C₂₁H₁₈N₂O₄S₂, %: C 61.44; H 4.42; N 6.82; S 15.62. Found, %: C 61.39; H, 4.48; N 6.85; S 15.59.

2.3. Antimicrobial activity.

2.3.1. Methodology of the diffusion method.

Antibacterial activity of compounds was evaluated by diffusion in peptone on nutrient medium (meat-extract agar for bacteria; wort agar for fungi). The microbial loading was 10⁹ cells (spores)/cm³. The required incubation periods were as follows: 24 h at 35 °C for bacteria and 48–72 h at 28–30 °C for fungi. The results were recorded by measuring the zones surrounding the disk. Control disk contained Vancomycin (for bacteria) or Nystatin (for fungi) as a standard.

2.3.2. Methodology of the serial dilution method.

Testing was performed in a flat-bottomed 96-well tissue culture plate. The tested compounds were dissolved in dimethyl sulfoxide (DMSO) to the necessary concentration. The exact volume of the solution of compounds was brought in a nutrient medium. The inoculum of bacteria and fungi was in a nutrient medium (meat-extract agar for bacteria; wort agar for fungi). The duration of incubation was 24–72 h at 37 °C for bacteria and 30 °C for fungi. The results were estimated according to the presence or absence of microorganism growth.

3. Results and Discussion

3.1. Chemistry.

In continuation of our research on the molecular design and the search of new biologically active derivatives of 9,10-anthracenedione [32-36], the new 2-((9,10-dioxo-9,10-
dihydroanthracenyl(amino)-2-oxoethyl-carbodithioates 3a-n were synthesized by the four-component one-pot two-step reaction of 2-chloro-N-(9,10-dioxo-9,10-dihydroanthracenyl)acetamide 1 or 2 with a series of in situ generated potassium salt of dithiocarbamic acids in DMF-H₂O medium at heating for 5 h (Scheme 1).

![Scheme 1](image)

**Scheme 1.** Synthesis of 2-((9,10-dioxo-9,10-dihydroanthracenyl)amino)-2-oxoethyl-carbodithioates 3a-n.

The structure of the synthesized 9,10-dioxoanthracenyl-dithiocarbamates 3a-n is clearly confirmed by the results of the NMR study. In particular, the ¹H NMR spectra of dithiocarbamates 3a-n contain the resonance signals of the CH₂ group of the oxoethyl fragment represented as a doublet of two protons at the range of 4.31-4.39 ppm. The proton of the secondary amino group, depending on the substitution position in the 9,10-anthracenedione fragment, is characterized by a broad singlet signal at the range of 12.40-12.64 ppm for 3a-i and 10.76-10.91 ppm for 3j-n. The dithiocarbamate substituent in the ¹³C NMR spectra is represented by a signal of thiocarbonyl carbon in a weaker field in the range of 189.81-197.03 ppm, while the signals of two carbonyl groups of anthracene ring hydrocarbons are located at the range of 181.62-186.89 ppm.
3.2 Investigation of antimicrobial activity.

Antibacterial and antifungal activities of the synthesized dithiocarbamates 3a-n were evaluated in vitro against the strains of *Escherichia coli* B-906, *Staphylococcus aureus* 209-P, *Mycobacterium luteum* B-917, *Candida tenuis* VKM Y-70, and *Aspergillus niger* VKM F-1119 by the diffusion technique [37] and by the serial dilution technique (determination of minimal inhibition concentrations MIC) [38]. Antibacterial agent Vancomycin and antifungal agent Nystatin were used as control (C).

The bacterial strains of *E. coli* and *S. aureus* appeared to be insensitive to the action of the dithiocarbamate derivatives of 2-chloro-N-acetamides 3a-n investigated by the diffusion technique in agar at concentrations of 0.1 and 0.5% (Table 1). Dithiocarbamates 3a, 3i, and 3j showed their antibacterial effect against the bacteria *M. luteum* at a concentration of 0.5% with a diameter of the inhibition zone d = 19, 20, and 18 mm, respectively. The test culture of *C. tenuis* appeared to be sensitive to the derivatives 3a, 3i, 3j, and 3n at a concentration of 0.5% (the diameters of the growth inhibition zone were 17-26 mm). The strain *S. aureus* to be low sensitive to the action of compound 3n at concentrations of 0.1 and 0.5% (Table 1).

| Compound | Concentration, % | Inhibition diameter of microorganism growth, mm |
|----------|------------------|-----------------------------------------------|
|          |                  | Bactericidal activity                          |
|          |                  | *E. coli* | *S. aureus* | *M. luteum* | *C. tenuis* | *A. niger* |
| 3a       | 0.5              | 0         | 0           | 19.0        | 17.0        | 7.0        |
|          | 0.1              | 0         | 0           | 12.0        | 10.0        | 0          |
| 3b       | 0.5              | 0         | 0           | 15.0        | 19.0        | 7.0        |
|          | 0.1              | 0         | 0           | 10.0        | 10.0        | 0          |
| 3c       | 0.5              | 0         | 0           | 12.0        | 0           | 9.0        |
|          | 0.1              | 0         | 0           | 0           | 0           | 7.0        |
| 3f       | 0.5              | 0         | 0           | 10.0        | 15.0        | 7.0        |
|          | 0.1              | 0         | 0           | 0           | 8.0         | 0          |
| 3i       | 0.5              | 0         | 0           | 20.0        | 20.0        | 7.0        |
|          | 0.1              | 0         | 0           | 13.0        | 14.0        | 0          |
| 3j       | 0.5              | 0         | 0           | 18.0        | 20.0        | 15.0       |
|          | 0.1              | 0         | 0           | 10.0        | 15.0        | 7.0        |
| 3l       | 0.5              | 0         | 0           | 10.0        | 0           | 7.0        |
|          | 0.1              | 0         | 0           | 0           | 0           | 0          |
| 3m       | 0.5              | 0         | 0           | 12.0        | 17.0        | 15.0       |
|          | 0.1              | 0         | 0           | 0           | 15.0        | 7.0        |
| 3n       | 0.5              | 0         | 12.0        | 15.0        | 26.0        | 15.0       |
|          | 0.1              | 0         | 9.0         | 10.0        | 17.0        | 7.0        |
| Control  | 0.5              | 14.0      | 15.0        | 18.0        | 19.0        | 20.0       |

* only compounds with positive results are included in the table

| Compound | Cultures of microorganisms / MIC, μg/ml |
|----------|----------------------------------------|
|          | *E. coli* | *S. aureus* | *M. luteum* | *C. tenuis* | *A. niger* |
| 3a       | +         | +           | 250.0        | 62.5        | 125.0       |
| 3i       | +         | 125.0       | 62.5         | 500.0       | 500.0       |
| 3j       | 125.0     | 125.0       | 3.9          | 125.0       | 62.5        |
| 3n       | 250.0     | 250.0       | 31.2         | 500.0       | 250.0       |
| Control  | 31.2      | 62.5        | 7.8          | 31.2        | 7.8         |

* only compounds with positive results are included in the table

An in vitro studies of the antibacterial and antifungal effect using the serial dilution technique showed the following (Table 2). The test culture of bacteria *M. luteum* was highly...
sensitive to the dithiocarbamate 3j with MIC = 3.9 μg/ml. Dithiocarbamate 3n caused an antibacterial effect against the strain of *M. luteum* at a concentration two times lower (MIC = 31.2 μg/ml) than its isomeric analog 3i (MIC = 62.5 μg/ml). The compounds 3i, 3j, and 3n showed the antibacterial effect against strains of bacteria *E. coli* and *S. aureus* with MIC 125-250 μg/ml. Strains of fungi *C. tenuis* and *A. niger* to be sensitive to the action of the dithiocarbamate derivatives 3a, 3i, 3j, and 3n at MIC 62.5-500 μg/ml.

4. Conclusions

Therefore, in this work, we carried out the four-component one-pot two-step facile synthesis of a new 2-dithiocarbamate-*N*-(9,10-dioxo-9,10-dihydroanthracenyl)acetamides 3a-n and their antibacterial and antifungal effects were investigated. The outcomes of our *in vitro* antimicrobial screening revealed the compounds with good antibacterial activity against strain *M. luteum* and antifungal effect against *C. tenuis*. The dithiocarbamate 3j showed higher antibacterial action at MIC 3.9 μg/ml in comparison with control. The obtained results show the perspective of further in-depth investigations of selected dithiocarbamates as antimicrobial agents.

Funding

This research was funded by the Ministry of Education and Science of Ukraine, Project number: 0119U002252.

Acknowledgments

This research has no acknowledgment.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Klemm, E.J.; Wong, V.K.; Dougan, G. Emergence of dominant multidrug-resistant bacterial clades: Lessons from history and whole-genome sequencing. *Proc. Natl. Acad. Sci. U. S. A.* 2018, 115, 12872–12877, https://doi.org/10.1073/pnas.1717162115.
2. Hawkey, P.M.; Warren, R.E.; Livermore, D.M.; McNulty, C.A.M.; Enoch, D.A.; Otter, J.A.; Wilson, A.P.R. Treatment of infections caused by multidrug-resistant gram-negative bacteria: report of the british society for antimicrobial chemotherapy/healthcare infection society/british infection association joint working party. *J. Antimicrob. Chemother.* 2018, 73, iii2–iii78, https://doi.org/10.1093/jac/dky027.
3. Youssi, H.; Ranque, S.; Rolain, J.M.; Bittar, F. In vitro polymyxin activity against clinical multidrug-resistant fungi. *Antimicrobial resistance & infection control* 2019, 8, https://doi.org/10.1186/s13756-019-0521-7.
4. Murugan, N.; Natarajan, D. Bionanomedicine for antimicrobial therapy – a case study from *Glycosmis pentaphylla* plant mediated silver nanoparticles for control of multidrug resistant bacteria. *Lett. Appl. NanoBioScience* 2018, 8, 523–540, https://doi.org/10.33263/LIANBS834.523540.
5. Sharma, D.; Sharma, S.; Sharma, J. Potential strategies for the management of drug-resistant tuberculosis. *J. Glob. Antimicrob. Resist.* 2020, 22, 210-214, https://doi.org/10.1016/j.jgar.2020.02.029.
6. Morel, C.M.; Lindahl, O.; Harbarth, S.; de Kraker, M.E.A.; Edwards, S.; Hollis, A. Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus. *J. Antibiot.* 2020, 73, 421–428, https://doi.org/10.1038/s41429-020-0300-y.
7. Murray, A.K. The Novel Coronavirus COVID-19 Outbreak: Global Implications for Antimicrobial Resistance. *Front. Microbiol.* 2020, 11, 1020, https://doi.org/10.3389/fmicb.2020.01020.
8. Kishida, N.; Nishiura, H. Accelerating reductions in antimicrobial resistance: Evaluating the effectiveness of an intervention program implemented by an infectious disease consultant. *Int. J. Infect. Dis.* 2020, 93, 175-181, https://doi.org/10.1016/j.ijid.2020.01.051.

https://biointerfaceresearch.com/ 7732
9. Balasegaram, M.; Piddock, L.J.V. The Global Antibiotic Research and Development Partnership (GARDP) Not-for-Profit Model of Antibiotic Development. ACS Infect. Dis. 2020, 6, 1295–1298, https://doi.org/10.1021/acsinfecdis.0c00101.

10. Kanchi, S.; Singh, P.; Bisetty, K. Dithiocarbamates as hazardous remediation agent: a critical review on progress in environmental chemistry for inorganic species studies of 20th century. Arabian Journal of Chemistry 2014, 7, 11–25, https://doi.org/10.1016/j.arabjc.2013.04.026.

11. Thebiti, A.; Chniti, I.; Sanhoury, M.A.; Chehidi, I.; Ouzari, H.I.; Boudabous, A. Antimicrobial activity of highly fluorinated thio carbamates and dithiocarbamates. Curr. Chem. Biol. 2019, 13, 120–128, https://doi.org/10.2174/2212796812666180907153901.

12. Odularu, A.T.; Ajibade, P.A. Dithiocarbamates: challenges, control, and approaches to excellent yield, characterization, and their biological applications. Bioinorg. Chem. Appl. 2019, https://doi.org/10.1155/2019/8260496.

13. Ge, Y.; Xu, L.W.; Liu, Y.; Sun, L.Y.; Gao, H.; Li, J.Q.; Yang, K. Dithiocarbamate as a valuable scaffold for the inhibition of metallo-β-lactamases. Biomolecules 2019, 9, https://doi.org/10.3390/biom9110699.

14. Balakrishnan, S.; Duraisamy, S.; Kasi, M.; Kandasamy, S.; Sarkar, R.; Kumarasamy, A. Syntheses, physicochemical characterization, antibacterial studies on potassium morpholine dithiocarbamate nickel (II), copper (II) metal complexes and their ligands. Heliyon 2019, 5, https://doi.org/10.1016/j.heliyon.2019.e01687.

15. Jiang, S.; Su, S.; Chen, M.; Peng, F.; Zhou, Q.; Liu, T.; Liu, L.; Xue, W. Antibacterial activities of novel dithiocarbamate-containing 4H-chromen-4-one derivatives. J. Agric. Food Chem. 2020, 68, 5641–5647, https://doi.org/10.1021/acs.jafc.0c01652.

16. Baghershouri, M.; Safa, K.D.; Adibkia, K.; Lotfipour, F. Synthesis and antibacterial evaluation of new sulfanyltetrazole derivatives bearing piperidine dithiocarbamate moiety. Synth. Commun. 2018, 48, 323–328, https://doi.org/10.1080/00397911.2017.1401639.

17. Quiroga, D.; Becerrra, L. D.; Coy-Barrera, E. Ultrasound-assisted synthesis, antifungal activity against fusarium oxysporum, and three-dimensional quantitative structure–activity relationship of N,S-dialkyl dithiocarbamates derived from 2-amino acids. ACS Omega 2019, 4, 13710–13720, https://doi.org/10.1021/acsomega.9b01098.

18. de Freitas Oliveira, J.W.; Rocha, H.A.O.; de Medeiros, W.M.T.Q.; Silva, M.S. Application of dithiocarbamates as potential new antitrypanosomatids-drugs: approach chemistry, functional and biological. Molecules 2019, 24, https://doi.org/10.3390/ molecules24152806.

19. Ramesh, P.; Rao, V.S.; Hong, Y.A.; Reddy, P.M.; Hu, A. Molecular design, synthesis, and biological evaluation of 2-hydroxy-3-chrysino dithiocarbamate derivatives. Molecules 2019, 24, https://doi.org/10.3390/molecules24173038.

20. Li, X.; Tolbert, W.D.; Hu, H.G.; Gohain, N.; Zou, Y.; Niu, F.; He, W.X.; Yuan, W.; Su, J.C.; Pazgier, M.; Lu, W. Dithiocarbamate-inspired side chain stapling chemistry for peptide drug design. Chem. Sci. 2019, 10, 1522–1530, https://doi.org/10.1039/C8SC03275K.

21. Adokoh, C.K. Therapeutic potential of dithiocarbamate supported gold compounds. RSC Adv. 2020, 10, 2975–2988, https://doi.org/10.1039/C9RA09682E.

22. Anusevicius, K.; Mickevicius, V.; Stasevych, M.; Zvarych, V.; Komarovskaya-Porokhnyavets, O.; Novikov, V.; Tarasova, O.; Gloriosoza, T.; Poroikov, V. Synthesis and chemoinformatics analysis of N-aryl-β-alanine derivatives. Res. Chem. Intermed. 2015, 41, 7517–7540, https://doi.org/10.1007/s11164-014-1841-0.

23. Malik, E.M.; Mueller, C.E. Anthraquinones as pharmacological tools and drugs. Medicinal Research Reviews 2016, 36, 705–748, https://doi.org/10.1002/med.21391.

24. Tikhomirov, A.S.; Shitl, A.A.; Shchekotikhin, A.E. Advances in the discovery of anthraquinone-based anticancer agents. Recent Pat. Anti-Cancer Drug Discovery 2018, 13, 159–183, https://doi.org/10.2174/1574892813666171206123114.

25. Mohamadzadeh, M.; Zarei, M.; Vessal, M. Synthesis, in vitro biological evaluation and in silico molecular docking studies of novel β-lactam-anthraquinone hybrids. Bioorg. Chem. 2019, 95, https://doi.org/10.1016/j.bioorg.2019.103515.

26. Zvarich, V.I.; Stasevych, M.V.; Stan’ko, O.V.; Komarovskaya-Porokhnyavets, E.Z.; Poroikov, V.V.; Rudik, A.V.; Lagunin, A.A.; Vovk, M.V.; Novikov, V.P. Computerized prediction, synthesis, and antimicrobial activity of new aminoacid derivatives of 2-chloro-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide. Pharm. Chem. J. 2014, 48, 582–586, https://doi.org/10.1007/s11194-014-1154-z.

27. Stasevych, M.; Zvarych, V.; Luniin, V.; Kopak, N.; Komarovska-Porokhnyavets, O.; Deniz, N.G.; Sayil, C.; Ozyurek, M.; Guclu, K.; Vovk, M.V.; Novikov, V. Synthesis, investigation of antimicrobial and antioxidant activity of anthraquinononylhydrazones. Monatsh. Chem. 2018, 149, 1111–1119, https://doi.org/10.1007/s00706-018-2157-3.

28. Zvarych, V.; Stasevych, M.; Novikov, V.; Rusanov, E.; Vovk, M.; Szweda, P.; Greeka, K.; Milewski, S. Anthra[1,2-d][1,3]triazine-4,7,12(3H)-triones as a new class of antistaphylococcal agents: synthesis and biological evaluation. Molecules 2019, 24, https://doi.org/10.3390/ molecules24244581.

29. Stasevych, M.V.; Zvarych, V.I.; Novikov, V.P.; Zagorodnyaya, S.D.; Povnitsa, O.Y.; Chaika, M.A.; Nesterkina, M.V.; Kravchenko, I.A.; Druzhilovskii, D.S.; Poroikov, V.V. 9,10-Anthraquinone
dithiocarbamates as potential pharmaceutical substances with pleiotropic actions: computerized prediction of biological activity and experimental validation. *Pharm. Chem. J.* **2020**, *53*, 905–913, https://doi.org/10.1007/s11094-020-02098-x.

30. Ramadhan, A.; Wardani, A.K.; Chang, C.I. Anthraquinone derivatives and its antibacterial properties from *paederia foetida* stems. *The Natural Products Journal* **2020**, *10*, https://doi.org/10.2174/2210315510666191224103057.

31. Armarego, W.L.F.; Chai, C. *Purification of Laboratory Chemicals*. 7th ed.; Elsevier: Oxford, UK, 2013; pp. 1–1024, https://doi.org/10.1016/C2009-0-64000-9.

32. Stasevych, M.; Zvarych, V.; Lunin, V.; Halenova, T.; Savchuk, O.; Dudchak, O.; Vovk, M.; Novikov, V. Novel anthraquinone-based derivatives as potent inhibitors for receptor tyrosine kinases. *Indian Journal of Pharmaceutical Sciences* **2015**, *77*, 634–637, https://doi.org/10.4103/0250-474X.169062.

33. Zvarych, V.; Stasevych, M.; Lunin, V.; Deniz, N.G.; Sayil, C.; Ozyurek, M.; Guclu, K.; Vovk, M.; Novikov, V. Synthesis and investigation of antioxidant activity of the dithiocarbamates derivatives of 9,10-anthracenedione. *Monatsh. Chem.* **2016**, *147*, 2093–2101, https://doi.org/10.1007/s00706-016-1839-y.

34. Stasevych, M.V.; Zvarych, V.I.; Stan’ko, O.V.; Vovk, M.V.; Novikov, V.P. Synthesis of 2-(N-benzoylimino)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)thiazoles. *Chem. Heterocycl. Compd.* **2014**, *49*, 1831–1833, https://doi.org/10.1007/s10593-014-1437-z.

35. Zvarych, V.I.; Stasevych, M.V.; Lunin, V.V.; Vovk, M.V.; Novikov, V.P. Synthesis of (1H-pyrrol-1-yl)anthracene-9,10-diones. *Chem. Heterocycl. Compd.* **2016**, *52*, 421–423, https://doi.org/10.1007/s10593-016-1904-9.

36. Stasevych, M.; Zvarych, V.; Musyanovych, R.; Novikov, V.; Vovk, M. Synthesis of N-benzoyl-N’-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-thioureas and quantum-chemical analysis of the reaction passing. *Chemistry & Chemical Technology* **2014**, *8*, 135–140, https://doi.org/10.23939/chcht08.02.135.

37. NCCLS. *Performance standards for antimicrobial disk susceptibility tests – fourth edition: approved standards*, document M2-A4, NCCLS: Villanova, PA, USA, 1990.

38. NCCLS. *Reference method for broth dilution antifungal susceptibility testing of conidium forming filamentous fungi: proposed standard*, document M38-P. NCCLS: Wayne, PA, USA, 1998.